How deadly is the Coronavirus?
Coronaviruses (CoV) are a large family of viruses that cause sickness from normal virus to serious ailments such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). An epic coronavirus (nCoV) is another strain that has not been recently recognized in people. Coronaviruses are zoonotic which means they are transmitted from animals to people. Common symptoms are respiratory side effects, fever, cough, brevity of breath and breathing challenges. In severe cases, it leads to pneumonia, severe acute respiratory syndrome, kidney failure and even it leads to death. Standard proposals to forestall contamination spread include hand washing, covering mouth and nose while coughing and sneezing, completely cooking meat and eggs.
- Middle East Respiratory Syndrome
- Severe Acute Respiratory Syndrome
Related Conference of How deadly is the Coronavirus?
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
How deadly is the Coronavirus? Conference Speakers
Recommended Sessions
- Adaptive immune system
- Autoimmune and Inflammatory Diseases
- Diabetes Vaccines
- Haematopoietic, Lymphoid Malignancies and Immune System Development
- HIV Vaccines
- How deadly is the Coronavirus?
- Human Vaccines-Infectious and Non Infectious
- Immunization and Bioterrorism
- Immunogenetics
- Immunotherapy
- Nanotechnology in Vaccine Delivery System
- Pediatric Vaccination
- Travel Immunization
- Vaccination for pregnant women
- Vaccine Adjuvants and Delivery Technologies
- Vaccines and Immunization
- Vaccines for Immune mediated Disease
- Vaccines for Unconventional Diseases
- Vaccines Preclinical and Clinical Trials
- Veterinary Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Bioinformatics and AI in Vaccine Design - Vaccine Immunology 2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Challenges in Vaccine Accessibility and Equity - Vaccine Immunology 2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Clinical Vaccinology and Immunotherapy - Vaccine Immunology 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases - Vaccine Immunology 2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Future Directions in Vaccine Research - Vaccine Immunology 2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Global Vaccination Strategies - Vaccine Immunology 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Human Microbiome and Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunology and Immune System Innovations - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Immunotherapy and Vaccines for Non-Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunotherapy in Cancer Treatment - Vaccine Immunology 2026 (France)
- Industry and Technology Innovations - Vaccine Immunology 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Maternal, Neonatal, and Geriatric Immunization - Vaccine Immunology 2026 (France)
- Microbiome-Targeted Vaccines - Vaccine Immunology 2026 (France)
- Nanotechnology and Advanced Delivery Systems - Vaccine Immunology 2026 (France)
- Nanotechnology in Vaccine Delivery - Vaccine Immunology 2026 (France)
- Next-Generation Vaccine Platforms - Vaccine Immunology 2026 (France)
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors - Vaccine Immunology 2026 (France)
- One Health Approach to Vaccine Development - Vaccine Immunology 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pandemic Preparedness and Response - Vaccine Immunology 2026 (France)
- Public Health and Global Immunization - Vaccine Immunology 2026 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The Economics of Vaccination - Vaccine Immunology 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Trust - Vaccine Immunology 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Production and Global Supply Chains - Vaccine Immunology 2026 (France)
- Vaccine Research and Development - Vaccine Immunology 2026 (France)
- Vaccine Safety and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine-Induced Immunity and Duration of Protection - Vaccine Immunology 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)

